Newsroom | 5589 results

FRANCFORT, Allemagne et GANZHOU, Chine--(BUSINESS WIRE)--Merz Therapeutics GmbH et Jiangxi Kvvit Pharmaceutical Co. Ltd. ont annoncé aujourd’hui avoir conclu un accord exclusif de licence et de collaboration concernant INBRIJA® (poudre pour inhalation de lévodopa) et son dispositif d’inhalation exclusif pour le traitement intermittent des fluctuations motrices épisodiques (épisodes OFF) chez les patients adultes atteints de la maladie de Parkinson (MP) traités par un inhibiteur de la lévodopa/d...

FRANKFURT, Deuschland & GANZHOU, China--(BUSINESS WIRE)--Die Merz Therapeutics GmbH und die Jiangxi Kvvit Pharmaceutical Co. Ltd. gaben heute bekannt, dass die Unternehmen eine exklusive Lizenz- und Kooperationsvereinbarung bezüglich INBRIJA® (Levodopa-Inhalationspulver) und dessen proprietärem Inhalationsgerät zur intermittierenden Behandlung episodischer motorischer Fluktuationen (OFF-Episoden) bei erwachsenen Patienten mit Parkinson-Krankheit (PD), die mit einem Levodopa/Dopa-Decarboxylase-H...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine is expected to join broad-market Russell 3000® Index & small-cap Russell 2000® Index at the conclusion of June 2026 Russell Reconstitution....

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios receives USPTO patent allowance for novel Bryoid therapeutics targeting Alzheimer’s, MS, HIV latency and cancer....

NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V. today announced a Data Use Agreement (DUA) under which Prilenia will provide CHDI with clinical data from the placebo arms of its PRIDE and PROOF studies for the purpose of advancing research into treatments for Huntington's disease (HD). “Collaboration which balances scientific rigor with data openness is an ethical and scientific imperative. Sharing data is key to accelerating and advancing knowledge and un...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r...

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro...

FRANKFURT, Germany & GANZHOU, China--(BUSINESS WIRE)--Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland Ch...

PORTO, Portugal--(BUSINESS WIRE)--Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease....